1 Information sur le médicament Swissmedic de Cinnageron® et Arlevert® (www.swissmedicinfo.ch) (accès le 1er. avril 2017).
2 Micromedex® 2,0, (version électronique). Truven Health Analytics, Greenwood Village, Colorado, USA. Disponible sur:
http://www.micromedexsolutions.com (accès le 1er avril 2017).
3 Cardoso F, Seppi K, Mair KJ, Wenning GK, Poewe W. Seminar on choreas. Lancet Neurol. 2006;5:589–602.
4 Micheli FE, Pardal MM, Giannaula R, Gatto M, Parera I, Paradiso G, et al. Movement disorders and depression due to flunarizine and cinnarizine. Mov Disord. 1989;4:139–46.
5 Martí-Massó JF, Poza JJ. Cinnarizine-induced parkinsonism: ten years later. Mov Disord. 1998;13:453–6.
6 Capellà D, Laporte JR, Castel JM, Tristán C, Cos A, Morales-Olivas FJ. Parkinsonism, tremor, and depression induced by cinnarizine and flunarizine. BMJ. 1988;297:722–23.
7 Daniel JR, Mauro VF. Extrapyramidal symptoms associated with calcium-channel blockers. Ann Pharmacother. 1995;29:73–5.